Skip to NavigationSkip to content

AbbVie VP joins UCB Pharma

Published on: 25/01/16

Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February 1, 2016.

Richetta has had a 20 year career in the pharma industry, and has commercial experience managing traditional pharmaceuticals and complex biologics. She joins UCB from Abbvie, where she was vice president of Western Europe and Canada. Prior to this she held several management positions at Abbott, GSK, Ipsen and Servier, successfully launching these companies’ key drugs on several international markets.

She will also hold the positions of executive vice president and member of the executive committee, and will report to chief executive Jean-Christophe Tellier. The position of head of the bone patient value unit of UCB was created last year as part of the company’s new patient value organisation. It had been filled ad interim by Iris Loew Friedrich, who had taken on that extra role in addition to her responsibilities as chief medical officer and head of the development and medical practices.

Jean-Christophe Tellier says: “We are very happy to welcome Pascale on our team to lead our bone patient value unit and take our investigational osteoporosis drug romosozumab through its next development steps. Romosozumab, which we develop in partnership with Amgen is progressing as planned with key milestones expected in the course of 2016.”

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches